WINT (Windtree Therapeutics) Shiller PE Ratio: (As of Sep. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Windtree Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Windtree Therapeutics  (OTCPK:WINT) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Windtree Therapeutics Shiller PE Ratio Related Terms


Windtree Therapeutics Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Windtree Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Windtree Therapeutics Shiller PE Ratio Chart

Windtree Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Windtree Therapeutics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

WINT vs LIPO, ITRMF, IOBTQ: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Windtree Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Windtree Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Windtree Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Windtree Therapeutics's Shiller PE Ratio falls into.



Windtree Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Windtree Therapeutics's E10 for the quarter that ended in Sep. 2025 is calculated as:

For example, Windtree Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2025 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2025 (Change)*Current CPI (Sep. 2025)
=-1.08/324.8000*324.8000
=-1.080

Current CPI (Sep. 2025) = 324.8000.

Windtree Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201512 -3,653,333.333 236.525 -5,016,817.108
201603 -4,633,666.667 238.132 -6,320,086.899
201606 -3,541,333.333 241.018 -4,772,361.677
201609 -2,787,666.667 241.428 -3,750,327.772
201612 -2,200,666.667 241.432 -2,960,570.817
201703 -4,109,333.333 243.801 -5,474,593.896
201706 -2,428,000.000 244.955 -3,219,425.609
201709 -1,535,400.000 246.819 -2,020,500.529
201712 107,521.739 246.524 141,661.911
201803 -196,173.913 249.554 -255,324.647
201806 -113,037.037 251.989 -145,698.541
201809 -145,444.444 252.439 -187,135.726
201812 -97,752.101 251.233 -126,376.242
201903 -27,466.387 254.202 -35,094.462
201906 -27,046.218 256.143 -34,295.732
201909 -29,941.176 256.759 -37,875.572
201912 -24,259.868 256.974 -30,663.044
202003 -21,493.421 258.115 -27,046.329
202006 -25,556.150 257.797 -32,198.348
202009 -23,989.362 260.280 -29,936.010
202012 -19,824.468 260.474 -24,720.268
202103 -15,370.497 264.877 -18,847.757
202106 -63,050.590 271.696 -75,374.064
202109 -13,849.916 274.310 -16,399.157
202112 -20,816.879 278.802 -24,251.341
202203 -12,859.177 287.504 -14,527.313
202206 -26,543.645 296.311 -29,095.700
202209 -5,594.483 296.808 -6,122.099
202212 -11,709.000 296.797 -12,813.752
202303 -77,085.000 301.836 -82,949.708
202306 -1,473.500 305.109 -1,568.596
202309 -773.500 307.789 -816.250
202312 -671.340 306.746 -710.853
202403 1,099.370 312.332 1,143.256
202406 -1,045.840 314.175 -1,081.209
202409 -211.380 315.301 -217.748
202412 0.265 315.605 0.273
202503 -4.630 319.799 -4.702
202506 -3.060 322.561 -3.081
202509 -1.080 324.800 -1.080

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Windtree Therapeutics Business Description

Address 2600 Kelly Road, Suite 100, Warrington, PA, USA, 18976-3622
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.